Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
607-02-008 ISMRM Abstract

Gadoquatrane: Dose selection and performance of a low dose for contrast-enhanced MRA based on non-clinical and clinical data

Primary: Cardiovascular - Vascular and Vessel Wall
Secondary: Contrast Mechanisms - Contrast Agents
607-02-008 · Quantitative and Multi-Contrast MRI: Methods and Applications · Thursday, 14 May, 1:40 PM–3:30 PM · Meeting Room 1.40
Keywords: Magnetic resonance angiography Gadolinium Based Contrast Agents Clinical-research Animal Model Non-clinical research
Accepted
Birte M Hofmann 1, Gregor Jost2,3, Chenshuang Lu4, Viktoriia Fursenko5, Alex Liu6, Petra K Palkowitsch3
1Radiology R&D, Bayer AG, Berlin, Germany
2Radiology, Bayer AG, Berlin, Germany
3Bayer AG, Berlin, Germany
4Clinical Statistics & Analytics, Bayer Pharma R&D, Whippany, United States of America
5Syneos Health LLC, United States of America
6Bayer Pharma R&D, Whippany, United States of America
Presenting Author: Birte M Hofmann

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1. Lohrke et al., Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent; Invest Radiol. 2022 Oct 1;57(10):629-638.
2. 2. Gruendemann S, Frenzel T, Lohrke J, Boyken J, Jost G, Berger M, Ulbrich HF, Pietsch H. In Vitro and In Vivo Stability Assessment of the Novel, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane. Invest Radiol. 2025 Nov 1;60(11):768-778
3. 3. Hofmann et al., Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults. Invest Radiol. 2024 Feb 1;59(2):140-149.
4. 4. Hofmann et al., Relationship of Dose and Signal Enhancement Properties of Gadoquatrane, a New Tetrameric, Macrocyclic Gadolinium-Based Contrast Agent, Compared With Gadobutrol: A Randomized Crossover Study in Healthy Adults. Invest Radiol. 2024 Dec 1;59(12):845-853.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/607-02-008